The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload


Sivgin S., Baldane S. , AKYOL G. , Keklik M. , KAYNAR L. , Kurnaz F. , ...More

TRANSFUSION AND APHERESIS SCIENCE, vol.49, no.2, pp.295-301, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.07.004
  • Title of Journal : TRANSFUSION AND APHERESIS SCIENCE
  • Page Numbers: pp.295-301
  • Keywords: Allogeneic haematopoietic stem cell, transplantation, Deferasirox, Iron overload, Survival, PRETRANSPLANTATION SERUM FERRITIN, MYELODYSPLASTIC SYNDROMES, MARROW-TRANSPLANTATION, THERAPY, ICL670, MORTALITY

Abstract

Introduction: Iron overload (10) has been shown to be an important cause of mortality and morbidity in patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). This study aimed to evaluate the possible effect of oral iron-chelation treatment (deferasirox) on survival in alloHSCT recipients in the posttransplant period.